BridgeBio Pharma Receivables 2018-2024 | BBIO
BridgeBio Pharma receivables from 2018 to 2024. Receivables can be defined as the total amount of collectibles for a company
- BridgeBio Pharma receivables for the quarter ending June 30, 2024 were $0.001B, a 92.34% decline year-over-year.
- BridgeBio Pharma receivables for 2023 were $0.002B, a 89.75% decline from 2022.
- BridgeBio Pharma receivables for 2022 were $0.017B, a 13.52% decline from 2021.
- BridgeBio Pharma receivables for 2021 were $0.02B, a INF% increase from 2020.
BridgeBio Pharma Annual Receivables
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$17 |
| 2021 |
$20 |
| 2020 |
$ |
| 2019 |
$3 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Receivables
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$235 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$5 |
| 2023-06-30 |
$9 |
| 2023-03-31 |
$11 |
| 2022-12-31 |
$17 |
| 2022-09-30 |
$25 |
| 2022-06-30 |
$23 |
| 2022-03-31 |
$11 |
| 2021-12-31 |
$20 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$46 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
|
| 2020-09-30 |
$8 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$3 |
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.045B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
